Today: 7 February 2026
Subscribe
Browse Category

NYSE:LLY News 29 November 2025 - 11 December 2025

Eli Lilly (LLY) After Hours: How a $6 Billion Bet, Fresh Oncology Data and Fed Rate Cut Set the Stage for December 11, 2025

Eli Lilly (LLY) After Hours: How a $6 Billion Bet, Fresh Oncology Data and Fed Rate Cut Set the Stage for December 11, 2025

Eli Lilly and Company (NYSE: LLY) closed just under the psychologically important $1,000 mark on Wednesday, December 10, 2025, then ticked slightly higher in after‑hours trading as investors digested a wave of company‑specific news against a backdrop of a fresh Federal Reserve rate cut.Yahoo Finance+1 Below is what happened after the bell on Dec. 10 and what traders and long‑term investors should know before the market opens on Dec. 11, 2025. LLY Stock After the Bell: Price Action at a Glance That’s the price backdrop. The real story, however, is today’s news flow—and there was a lot of it. Today’s
11 December 2025
····
Eli Lilly (LLY) Stock Near $1 Trillion: Zepbound Price Cuts, New $6B Plant and 2026 Dividend Hike – Is It Still a Buy?

Eli Lilly (LLY) Stock Near $1 Trillion: Zepbound Price Cuts, New $6B Plant and 2026 Dividend Hike – Is It Still a Buy?

Updated: December 10, 2025 Key takeaways LLY stock today: price, performance and valuation snapshot As of mid‑day trading on December 10, 2025, Eli Lilly (NYSE: LLY) is changing hands at around $980 per share, down slightly on the day and just below its recent all‑time high above $1,050. That price values Lilly at roughly $930–$1,000+ billion in market cap, depending on intraday moves, placing it in the same league as mega‑cap tech giants and making it the first healthcare company ever to cross the $1 trillion mark. Reuters Year to date, Reuters reports that LLY shares are up more than
10 December 2025
·····
Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax Société Anonyme (Euronext Paris: ABVX, Nasdaq: ABVX) is back in the spotlight on December 10, 2025, after its share price spiked again on fresh takeover speculation involving U.S. pharma giant Eli Lilly. The move caps an extraordinary year in which the French biotech has transformed from a relatively obscure name into a multibillion‑euro inflammatory bowel disease (IBD) contender.Reuters+1 Below is a detailed rundown of today’s news, the fundamental drivers, and the latest forecasts and analyses being published about Abivax. 1. Abivax stock today: how big is the move? On December 10, 2025, Abivax shares on Euronext Paris traded around
10 December 2025
·······
Eli Lilly’s $6 Billion Huntsville Plant: 450 High‑Paying Jobs, GLP‑1 Drug Boom and Alabama’s Biggest Industrial Bet

Eli Lilly’s $6 Billion Huntsville Plant: 450 High‑Paying Jobs, GLP‑1 Drug Boom and Alabama’s Biggest Industrial Bet

HUNTSVILLE, Ala. — December 9, 2025 Eli Lilly and Company will invest more than $6 billion in a new advanced pharmaceutical manufacturing campus in Huntsville, Alabama, creating 450 high‑value permanent jobs and an estimated 3,000 construction jobs in what state leaders are calling the largest initial private industrial investment in Alabama history. City of Huntsville+2governor.alabama.gov+2 The facility, planned for a 260‑acre site at the northeast corner of I‑565 and Greenbrier Parkway in Huntsville‑Limestone County, will manufacture active pharmaceutical ingredients (APIs) for small‑molecule and peptide medicines, including orforglipron, Lilly’s first oral GLP‑1 obesity drug now heading toward global regulatory submissions. City
10 December 2025
··
Eli Lilly (LLY) Stock on December 9, 2025: Jaypirca Breakthrough, Adverum Deal and Zepbound Price Cuts Reframe the Outlook

Eli Lilly (LLY) Stock on December 9, 2025: Jaypirca Breakthrough, Adverum Deal and Zepbound Price Cuts Reframe the Outlook

Eli Lilly and Company (NYSE: LLY) is once again in the spotlight. As of early trading on December 9, 2025, Eli Lilly stock is hovering around $997 per share, roughly 10% below its late‑November all‑time high but still up about 30% year to date and about 25% over the past 12 months.FinanceCharts Today’s story is about more than the share price: fresh Phase 3 cancer data for Jaypirca, the completed acquisition of Adverum, a higher 2026 dividend, Nobel laureate Carolyn Bertozzi rejoining the board, and an ongoing price reset for blockbuster obesity drug Zepbound. Together they reshape how investors are
9 December 2025
····
Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly and Company (NYSE: LLY) spent Monday, December 8, 2025, digesting a wave of news: a major reimbursement win for Mounjaro in China, a 15% dividend hike, new leukemia drug data, and the return of Nobel laureate Carolyn Bertozzi to its board. At the same time, intensifying competition and price cuts in the weight‑loss drug market kept pressure on the stock. By the closing bell, Lilly shares were trading just under the psychologically important $1,000 level, still near a trillion‑dollar valuation but roughly 10% below recent highs. StockAnalysis Key takeaways for LLY before the December 9, 2025 open How
9 December 2025
·······
Eli Lilly (LLY) Stock on December 8, 2025: China Insurance Win, Trillion‑Dollar Status and What Comes Next for Investors

Eli Lilly (LLY) Stock on December 8, 2025: China Insurance Win, Trillion‑Dollar Status and What Comes Next for Investors

Updated: December 8, 2025 – For informational purposes only, not investment advice. Key takeaways 1. Where Eli Lilly (LLY) stands on December 8, 2025 As U.S. markets trade on Monday, Eli Lilly and Company (NYSE: LLY) is changing hands near $1,010 per share, roughly flat versus Friday’s close around $1,010.31 and modestly below late‑November highs near $1,110.TechStock² The recent pullback follows: Even after that cooling‑off, Lilly still trades at roughly 50x expected earnings, far above peers like Abbott Laboratories around 15–16x.24/7 Wall St.+1 That valuation embeds very high expectations for durable growth in obesity, diabetes and related metabolic therapies. 2.
8 December 2025
·····
Eli Lilly (LLY) Stock: Key Catalysts to Watch Before the Market Opens on December 8, 2025

Eli Lilly (LLY) Stock: Key Catalysts to Watch Before the Market Opens on December 8, 2025

As Wall Street heads into Monday’s session, Eli Lilly and Company (NYSE: LLY) sits at the center of several big storylines: Chinese market access for its Alzheimer’s drug, a fresh FDA decision and new data for cancer therapy Jaypirca, price cuts for blockbuster obesity drug Zepbound, and a wave of institutional positioning. Below is a structured look at what matters for Eli Lilly stock before the U.S. market opens on Monday, December 8, 2025. 1. Where LLY Stock Stands After a Choppy Week In short, LLY heads into Monday as a mega‑cap growth stock that has cooled slightly but still
7 December 2025
·····
Eli Lilly (LLY) Stock Outlook: Can the Obesity-Drug Giant Keep Justifying a $1,000 Share Price?

Eli Lilly (LLY) Stock Outlook: Can the Obesity-Drug Giant Keep Justifying a $1,000 Share Price?

Updated: December 5, 2025 Eli Lilly and Company (NYSE: LLY) remains one of the most closely watched stocks in global markets as investors weigh eye‑popping growth in obesity and diabetes drugs against equally eye‑popping valuations and rising political pressure on drug prices. On December 5, 2025, Lilly shares are trading just above the $1,000 mark after recently touching an historic $1 trillion market capitalization, the first time a healthcare company has reached that milestone.CoinCentral At the same time, the company is cutting prices on flagship obesity drug Zepbound, navigating new U.S. “most‑favored‑nation” pricing rules, and preparing to ask regulators for
5 December 2025
·····
Eli Lilly (LLY) Stock on December 2, 2025: Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker

Eli Lilly (LLY) Stock on December 2, 2025: Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker

Eli Lilly’s stock is trading just below record highs after a historic run driven by obesity and diabetes drugs. Fresh price cuts, powerful earnings and evolving obesity guidelines are reshaping the outlook as of December 2, 2025. Eli Lilly Stock Today: High Price, High Expectations As of mid‑day on December 2, 2025, Eli Lilly and Company (NYSE: LLY) is trading around $1,057–$1,060 per share, down roughly 1–2% on the day but still close to its recent record highs.MarketBeat At this level: In short, LLY is priced as a hyper‑growth stock, not a traditional defensive pharma name. The rest of the
2 December 2025
·····
Eli Lilly (LLY) Stock on December 1, 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Outlook

Eli Lilly (LLY) Stock on December 1, 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Outlook

As of December 1, 2025, Eli Lilly and Company (NYSE: LLY) is trading around $1,075 per share, giving the drugmaker a market capitalization of roughly $1.0–1.02 trillion and cementing its status as the first pharmaceutical company to enter the trillion‑dollar club. MarketBeat+1 But today’s story is not just about the share price. Fresh Zepbound price cuts, new World Health Organization (WHO) guidance on GLP‑1 obesity drugs, and ongoing debate over valuation vs. growth are shaping how investors look at Eli Lilly stock heading into 2026. Below is a detailed, news‑driven look at LLY stock on December 1, 2025, including the
1 December 2025
·····
Eli Lilly (LLY) Stock Dips After Trillion‑Dollar Surge: November 29, 2025 Update for Investors

Eli Lilly (LLY) Stock Dips After Trillion‑Dollar Surge: November 29, 2025 Update for Investors

Eli Lilly and Company (NYSE: LLY) is catching its breath after one of the wildest runs any pharmaceutical stock has ever seen. On November 29, 2025, the share price is easing off record highs, but the company is still hovering near the rarefied air of a trillion‑dollar valuation and sitting on massive gains for the year. Smartkarma+1 This piece walks through what’s happening with Eli Lilly’s stock today, why it ran so hard in November, how new U.S. drug‑pricing deals and obesity drugs feed into the story, and what risks are starting to flash on the dashboard. Eli Lilly Stock
29 November 2025
·····
1 … 10 11 12 13

Stock Market Today

SGX share price dips at week’s end after record profit; what investors watch next

SGX share price dips at week’s end after record profit; what investors watch next

7 February 2026
Singapore Exchange shares closed 0.4% lower at S$17.57 on Friday, despite reporting record half-year results and a higher dividend earlier in the week. Broker targets diverged after the update, with Maybank and DBS raising targets while Citi stayed bearish. Investors are watching for signs of momentum from derivatives and equity-market reforms as the next session opens Monday.
South32 share price drops 4% in ASX rout — what investors watch before results

South32 share price drops 4% in ASX rout — what investors watch before results

7 February 2026
South32 shares fell 4.1% to A$4.41 Friday as Australian miners dropped in the worst ASX session since April 2025. The S&P/ASX 200 lost 2%, erasing almost A$70 billion in value. South32’s half-year results and interim dividend decision are set for Feb. 12. Markets reopen Monday with investors watching for further volatility.
Go toTop